These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 30520243)

  • 1. Effect of baseline body mass index on glycemic control and weight change with exenatide monotherapy in Chinese drug-naïve type 2 diabetic patients.
    Deng H; Lin S; Yang X; Lv J; Luo S; Zeng L; Weng J; Xu W;
    J Diabetes; 2019 Jul; 11(7):509-518. PubMed ID: 30520243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of baseline BMI on glycemic control and weight change with metformin monotherapy in Chinese type 2 diabetes patients: phase IV open-label trial.
    Ji L; Li H; Guo X; Li Y; Hu R; Zhu Z
    PLoS One; 2013; 8(2):e57222. PubMed ID: 23468941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.
    McAdam-Marx C; Nguyen H; Schauerhamer MB; Singhal M; Unni S; Ye X; Cobden D
    Clin Ther; 2016 Dec; 38(12):2642-2651. PubMed ID: 27889301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of baseline body mass index status on glucose lowering and weight change during sitagliptin treatment for type 2 diabetics.
    Chen JF; Chang CM; Kuo MC; Tung SC; Tsao CF; Tsai CJ
    Diabetes Res Clin Pract; 2016 Oct; 120():8-14. PubMed ID: 27498072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity.
    Sun W; Zeng C; Liao L; Chen J; Wang Y
    Curr Med Res Opin; 2016 Aug; 32(8):1389-96. PubMed ID: 27052634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trial.
    Kang C; Qiao Q; Tong Q; Bai Q; Huang C; Fan R; Wang H; Kaliannan K; Wang J; Xu J
    Sci Rep; 2021 Oct; 11(1):20062. PubMed ID: 34625598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
    Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
    Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial.
    Yang J; Xiao W; Guo L; Li Q; Zhong L; Yang J; Yang J; Gao Y; Tian Q; Hong T
    Acta Diabetol; 2020 Aug; 57(8):991-1000. PubMed ID: 32206903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
    Guja C; Frías JP; Somogyi A; Jabbour S; Wang H; Hardy E; Rosenstock J
    Diabetes Obes Metab; 2018 Jul; 20(7):1602-1614. PubMed ID: 29473704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea.
    Shin Y; Moon JH; Chin HJ; Ferrannini E; Lim S
    Endocrinol Metab (Seoul); 2020 Jun; 35(2):329-338. PubMed ID: 32615717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.
    Shao N; Kuang HY; Hao M; Gao XY; Lin WJ; Zou W
    Diabetes Metab Res Rev; 2014 Sep; 30(6):521-9. PubMed ID: 24823873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exenatide versus glibenclamide in patients with diabetes.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Diabetes Technol Ther; 2010 Mar; 12(3):233-40. PubMed ID: 20151774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exenatide Once Weekly: Effectiveness, Tolerability, and Discontinuation Predictors in a Real-world Setting.
    Di Dalmazi G; Coluzzi S; Baldassarre MPA; Sorbo SE; Dell'Aquila S; Febo F; Ginestra F; Graziano G; Rossi MC; Consoli A; Formoso G
    Clin Ther; 2020 Sep; 42(9):1738-1749.e1. PubMed ID: 32753164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes.
    Liu L; Yan H; Xia M; Zhao L; Lv M; Zhao N; Rao S; Yao X; Wu W; Pan B; Bian H; Gao X
    Diabetes Metab Res Rev; 2020 Jul; 36(5):e3292. PubMed ID: 31955491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus.
    Zhang J; Xian TZ; Teng Y; Wang X; Wu MX; Li C; Wang W; Man F; Zhang X; Wang X; Guo LX
    Int J Clin Pract; 2022; 2022():7128859. PubMed ID: 37214201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
    Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
    Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus.
    Wu JD; Xu XH; Zhu J; Ding B; Du TX; Gao G; Mao XM; Ye L; Lee KO; Ma JH
    Diabetes Technol Ther; 2011 Feb; 13(2):143-8. PubMed ID: 21284481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
    Ji L; Ma J; Li H; Mansfield TA; T'joen CL; Iqbal N; Ptaszynska A; List JF
    Clin Ther; 2014 Jan; 36(1):84-100.e9. PubMed ID: 24378206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.
    Yuan GH; Song WL; Huang YY; Guo XH; Gao Y
    Chin Med J (Engl); 2012 Aug; 125(15):2677-81. PubMed ID: 22931974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender-related different effects of a combined therapy of Exenatide and Metformin on overweight or obesity patients with type 2 diabetes mellitus.
    Quan H; Zhang H; Wei W; Fang T
    J Diabetes Complications; 2016; 30(4):686-92. PubMed ID: 26873871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.